viewFSD Pharma

FSD Pharma and Therapix Biosciences in $48M deal to form medical cannabis company

The transaction for 130 million class B shares account for 10% of the company

Cannabis products
FSD Pharma through its wholly-owned subsidiary FV Pharma is a licensed producer of marijuana

Canada's FSD Pharma Inc (CSE:HUGE) said it is acquiring Therapix Biosciences Ltd (NASDAQ:TRPX) for $48 million in stock to create a company focused on the research and development of cannabinoid treatments.

Therapix Biosciences shareholders will receive $48 million of FSD stock upon closing of the transaction, a joint statement by both companies said.

The transaction is structured at a fixed price of $48 million representing approximately 130 million class B subordinate shares of FSD Pharma and nearly 10% of the company at this time. The final number of class B subordinated shares and percentage ownership of the company will fluctuate based on the 20 day average of FSD Pharma stock's closing price on the date the transaction is finalized.

The terms will be superseded by a definitive agreement, which FSD Pharma and Therapix intend to execute within 30 days.

READ: FSD Pharma Inc. goes public, progresses with business plan

"The intended acquisition of Therapix Biosciences at this time is a pivotal step in the evolution of our company by entering the high-value medical cannabis market," Raza Bokhari, a director of FSD Pharma and chairman of the M&A committee, said.

Shares Therapix soared 68.55% to US$7.45 in the premarket on Tuesday, having closed 2.79% higher at US$4.42 on Monday.

FSD stock in Canada closed on Monday 18.64% lower at C$0.48. In New York, the stock was 19.6% lower at US$0.36.

"In addition to growing products for the direct to consumer retail cannabis market in Canada , we are now developing a new class of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia, irritable bowel syndrome and several other disease areas," Bokhari added.

READ: Therapix Bio Sciences shares rocket due to rosy trial for Tourette syndrome treatment

The acquisition allows FSD to step into several research programs such as Therapix' investigator-initiated Phase IIa study at Yale University Medical Center in the US for Tourette syndrome, subsequent preparations for starting Phase 2b studies at the Hannover and Munich University Medical Schools in Germany for Tourette, and collaboration with Assuta Medical Centers in Israel to develop therapeutic products in the field of sleeping disorders.

FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations. The company is based in Cobourg, Ontario.

Therapix Biosciences is a specialty clinical-stage pharmaceutical company.  The company is based in Israel.

Reporting by Rene Pastor, contactable on rene.pastor@proactiveinvestors.com

Quick facts: FSD Pharma

Price: 3.56 CAD

Market: CSE
Market Cap: $52.41 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...


FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat...

2 weeks, 2 days ago

3 min read